Cite
HARVARD Citation
Wells, A. et al. (2014). SAT0382 Palace 4, A Phase 3, Randomized, Controlled TRIAL of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-WEEK) Improvements in Physical Function. Annals of the rheumatic diseases. p. 732. [Online].